AFRICAN AMERICAN ANTIPLATELET STROKE PREVENTION STUDY (AAASPS)

该方案为多中心随机双盲试验，采用 用于检测噻氯匹定疗效的处理分析 盐酸阿司匹林与阿司匹林预防复发的比较 中老年人群的卒中、血管死亡和心肌梗死 老年非裔美国人非心源性缺血性卒中患者。 这项试验还将研究不良体验和 替氯匹定和阿司匹林在非裔美国人中的安全性 非心源性缺血性卒中患者。审判将会进行 在芝加哥地区，那里有大量的中年人和 年长的非裔美国人。 这场审判很重要，因为非洲裔美国人承受着过度的负担 中风风险和中风死亡率与她的种族和民族的比较 在美国的团体。非洲裔美国人和其他少数民族一直是 在生物医学研究中代表性不足，而且没有大规模 主要关注二级中风预防的临床试验 在非裔美国人身上。初步数据收集自非白人， 以非裔美国人为主的替氯匹定阿司匹林卒中患者 研究(TASS)表明噻氯匹定比阿司匹林更有效 中风和死亡的二级预防，非致命和致命的 卒中。发生严重不良事件的风险也很低，并没有 在接受噻氯匹定的组中与该组基本不同 用阿司匹林治疗。

The proposal is a multi center randomized double blind trial using intention to treat analyses to test the efficacy of ticlopidine hydrochloride versus aspirin in the secondary prevention of recurrent stroke, vascular death and myocardial infarction among middle aged and elderly African American patients with non-cardioembolic ischemic stroke. The trial will also study differences in adverse experiences and the safety profile between ticlopidine and aspirin in the African American non-cardioembolic ischemic stroke patients. The trial will be conducted in teh Chicago area which has a large population of middle aged and elderly African Americans. The trial is important as African Americans suffer an excess burden of stroke risk and stroke mortality as compared to toher racial and ethnic groups in the US. African Americans and other minorities have been underrepresented in biomedical research, and there has been no large scale clinical trial that has focused primarily on secondary stroke prevention in African Americans. Preliminary data collected from nonwhite, predominantly African American patients, in the Ticlopidine Aspirin Stroke Study (TASS) suggest that ticlopidine is more effective than aspirin in the secondary prevention of stroke and death, and nonfatal and fatal stroke. The risk of serious adverse events was also low and did not differ substantially in the group receiving ticlopidine from the group treated with aspirin.